Clinical trials: Endocrine System Disorder
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes
This trial is conducted in Asia and South Africa. The aim of this trial is to compare the efficacy and safety of repaglinide plus insulin NPH (insulin Neutral Protamine Hagedorn) with insulin NPH alone in subjects with type 2…
- Trial name
- NCT01562561
- Testing
- repaglinide, insulin NPH
- Where
- 12 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 213 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.
- Trial name
- NCT05248841
- Testing
- HEC-Glargine, US-Lantus
- Where
- South Africa
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Primary Objective: -To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin glargine).
- Trial name
- NEWLAN (NCT02606357)
- Testing
- INSULIN GLARGINE
- Where
- Jordan
- Volunteers
- 242 people
- Sponsor
- Sanofi
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Trial name
- NCT05543928
- Testing
- CTAP101
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- OPKO Health, Inc.
Pancreatic Cancer
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine [AG]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive…
- Trial name
- NCT07079228
- Testing
- QLS31905, Nab-paclitaxel., Gemcitabine
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the effect of NNC 90-1170 (liraglutide) on pulsatile insulin secretion and insulin secretion after a standard meal in subjects with type 2 diabetes.
- Trial name
- NCT01507311
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965509
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy…
- Trial name
- NCT06829563
- Testing
- RZ-629, Fasted, Fed
- Where
- Australia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Rezubio Pharmaceuticals Co., Ltd.
Healthy Volunteers, Hepatic Insufficiency
A Single Dose Study of LY2605541 in Participants With Liver Impairment
The primary purpose of this study is to help answer the following research questions: To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those…
- Conditions
- Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2
- Trial name
- NCT01751399
- Testing
- LY2605541
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
This is a Phase 1, randomized, double-blind, placebo-controlled, first-in-human (FIH) study to evaluate the safety, tolerability, food effect (FE), pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered XW014 in…
- Trial name
- NCT05579314
- Testing
- XW014
- Where
- 3 sites in United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences USA Co., Ltd.
Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
- Trial name
- KEYNOTE144 (NCT02362048)
- Testing
- ACP-196, ACP-196 in combination with pembrolizumab
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Acerta Pharma BV
Obesity, Type 2 Diabetes
MagDI Canada Study
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial…
- Trial name
- NCT06467955
- Testing
- Magnet System, DI Biofragmentable
- Where
- 3 sites in Canada
- Volunteers
- 60 people
- Sponsor
- GT Metabolic Solutions, Inc.
Diabetes Mellitus, Type 2
A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents
The purpose of this study is to evaluate the safety and glycemic control of SHR-3167 fixed-dose titration and individualized-dose titration in adults with Type 2 Diabetes inadequately controlled with oral antihyperglycemic agents.
- Trial name
- NCT07472725
- Testing
- SHR-3167 Injection
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus
To Evaluate the Efficacy and Safety of Multi-parameter Non-Invasive Glucose Sensors for for Blood Glucose Measurement
This was a prospective, multicenter, open-label, self-controlled study to evaluate the efficacy and safety of multi-parameter non-invasive glucose meters for blood glucose measurement，planned enrollment of 200 patients with type…
- Trial name
- NCT06017349
- Testing
- Non-invasive glucose meter, EKF analyzer, Accu-Chek Guide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Diabetes Mellitus, Type 2
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
The purpose of this study is to demonstrate that the rosiglitazone/glimepiride fixed-dose combination tablet will safely and effectively control glycemia as first-line oral therapy in drug naïve subjects with type 2 diabetes.
- Trial name
- NCT01453049
- Testing
- rosiglitazone/glimepiride fix dose combination, glimepiride
- Where
- 12 sites in China
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluates a new test formulation of a glucose lowering drug, insulin lispro, delivered by an insulin pump continuously under the skin.
- Trial name
- NCT02623478
- Testing
- Insulin Lispro
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain their target blood glucose levels on a single therapy. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in…
- Trial name
- NCT00138606
- Testing
- vildagliptin
- Where
- 2 sites in United States, Germany
- Volunteers
- 179 people
- Sponsor
- Novartis
Male Hypogonadism, Sexual Dysfunction
D-chiroinositol Administration in Hypogonadal Males
D-chiroinositol (DCI), is known as second messenger of insulin pathway, but recently several works have reported the influence of DCI on steroidogenesis.
- Trial name
- NCT04708249
- Testing
- D-chiroinositol
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Lo.Li.Pharma s.r.l
Type 2 Diabetes Mellitus (T2DM)
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
- Trial name
- Optimum 1 (NCT06777238)
- Testing
- GZR18
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Gan & Lee Pharmaceuticals.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.